AustralieFrV1, Istex, Checkpoint, bibRecord, 000386

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

Identifieur interne : 000386 ( Istex/Checkpoint ); précédent : 000385; suivant : 000387

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

Auteurs : J. Yale [Canada] ; G. Bakris [États-Unis] ; B. Cariou [France] ; D. Yue [Australie] ; E. David-Neto [Brésil] ; L. Xi [États-Unis] ; K. Figueroa [États-Unis] ; E. Wajs [Belgique] ; K. Usiskin [États-Unis] ; G. Meininger [États-Unis]

Source :

Diabetes, Obesity and Metabolism [ 1462-8902 ] ; 2013-05.

RBID : ISTEX:3E46F81A4B18835C6DC50A5868041B88751EAA96

Descripteurs français

Wicri :
- topic : Diabète, Glucose.

English descriptors

Abstract

Canagliflozin is a sodium glucose co‐transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR) ≥30 and <50 ml/min/1.73 m2].

Url:

https://api.istex.fr/document/3E46F81A4B18835C6DC50A5868041B88751EAA96/fulltext/pdf

DOI: 10.1111/dom.12090

Affiliations:

Australie, Belgique, Brésil, Canada, France, États-Unis
Illinois, Pays de la Loire, Québec, État de São Paulo
Chicago, Montréal, Nantes, São Paulo

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 000B63
to stream Istex, to step Curation: 000B63

Links to Exploration step

ISTEX:3E46F81A4B18835C6DC50A5868041B88751EAA96

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease</title>
<author><name sortKey="Yale, J" sort="Yale, J" uniqKey="Yale J" first="J." last="Yale">J. Yale</name>
</author>
<author><name sortKey="Bakris, G" sort="Bakris, G" uniqKey="Bakris G" first="G." last="Bakris">G. Bakris</name>
</author>
<author><name sortKey="Cariou, B" sort="Cariou, B" uniqKey="Cariou B" first="B." last="Cariou">B. Cariou</name>
</author>
<author><name sortKey="Yue, D" sort="Yue, D" uniqKey="Yue D" first="D." last="Yue">D. Yue</name>
</author>
<author><name sortKey="David Eto, E" sort="David Eto, E" uniqKey="David Eto E" first="E." last="David-Neto">E. David-Neto</name>
</author>
<author><name sortKey="Xi, L" sort="Xi, L" uniqKey="Xi L" first="L." last="Xi">L. Xi</name>
</author>
<author><name sortKey="Figueroa, K" sort="Figueroa, K" uniqKey="Figueroa K" first="K." last="Figueroa">K. Figueroa</name>
</author>
<author><name sortKey="Wajs, E" sort="Wajs, E" uniqKey="Wajs E" first="E." last="Wajs">E. Wajs</name>
</author>
<author><name sortKey="Usiskin, K" sort="Usiskin, K" uniqKey="Usiskin K" first="K." last="Usiskin">K. Usiskin</name>
</author>
<author><name sortKey="Meininger, G" sort="Meininger, G" uniqKey="Meininger G" first="G." last="Meininger">G. Meininger</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3E46F81A4B18835C6DC50A5868041B88751EAA96</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1111/dom.12090</idno>
<idno type="url">https://api.istex.fr/document/3E46F81A4B18835C6DC50A5868041B88751EAA96/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000B63</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B63</idno>
<idno type="wicri:Area/Istex/Curation">000B63</idno>
<idno type="wicri:Area/Istex/Checkpoint">000386</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000386</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease</title>
<author><name sortKey="Yale, J" sort="Yale, J" uniqKey="Yale J" first="J." last="Yale">J. Yale</name>
<affiliation wicri:level="3"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Royal Victoria Hospital and McGill University, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">Canada</country>
</affiliation>
</author>
<author><name sortKey="Bakris, G" sort="Bakris, G" uniqKey="Bakris G" first="G." last="Bakris">G. Bakris</name>
<affiliation wicri:level="3"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, The University of Chicago Medicine, IL, Chicago</wicri:regionArea>
<placeName><settlement type="city">Chicago</settlement>
<region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cariou, B" sort="Cariou, B" uniqKey="Cariou B" first="B." last="Cariou">B. Cariou</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Endocrinology & Center of Clinical Investigation, Nantes University Hospital, Nantes</wicri:regionArea>
<placeName><region type="region">Pays de la Loire</region>
<region type="old region">Pays de la Loire</region>
<settlement type="city">Nantes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yue, D" sort="Yue, D" uniqKey="Yue D" first="D." last="Yue">D. Yue</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Diabetes Centre, Royal Prince Alfred Hospital,University of Sydney, Camperdown</wicri:regionArea>
<wicri:noRegion>Camperdown</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="David Eto, E" sort="David Eto, E" uniqKey="David Eto E" first="E." last="David-Neto">E. David-Neto</name>
<affiliation wicri:level="3"><country xml:lang="fr">Brésil</country>
<wicri:regionArea>Núcleo Avançado de Netrologia, Hospital Sírio‐Libanês, São Paulo</wicri:regionArea>
<placeName><settlement type="city">São Paulo</settlement>
<region type="state">État de São Paulo</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Xi, L" sort="Xi, L" uniqKey="Xi L" first="L." last="Xi">L. Xi</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Biotech, Inc, PA, Spring House</wicri:regionArea>
<wicri:noRegion>Spring House</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Figueroa, K" sort="Figueroa, K" uniqKey="Figueroa K" first="K." last="Figueroa">K. Figueroa</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research & Development, LLC, NJ, Raritan</wicri:regionArea>
<wicri:noRegion>Raritan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wajs, E" sort="Wajs, E" uniqKey="Wajs E" first="E." last="Wajs">E. Wajs</name>
<affiliation wicri:level="1"><country xml:lang="fr">Belgique</country>
<wicri:regionArea>Janssen Research & Development, Beerse</wicri:regionArea>
<wicri:noRegion>Beerse</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Usiskin, K" sort="Usiskin, K" uniqKey="Usiskin K" first="K." last="Usiskin">K. Usiskin</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research & Development, LLC, NJ, Raritan</wicri:regionArea>
<wicri:noRegion>Raritan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Meininger, G" sort="Meininger, G" uniqKey="Meininger G" first="G." last="Meininger">G. Meininger</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Janssen Research & Development, LLC, NJ, Raritan</wicri:regionArea>
<wicri:noRegion>Raritan</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Diabetes, Obesity and Metabolism</title>
<title level="j" type="alt">DIABETES, OBESITY AND METABOLISM</title>
<idno type="ISSN">1462-8902</idno>
<idno type="eISSN">1463-1326</idno>
<imprint><biblScope unit="vol">15</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="463">463</biblScope>
<biblScope unit="page" to="473">473</biblScope>
<biblScope unit="page-count">11</biblScope>
<publisher>Blackwell Publishing Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2013-05">2013-05</date>
</imprint>
<idno type="ISSN">1462-8902</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1462-8902</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjustment period</term>
<term>Adverse event</term>
<term>Advisory panels</term>
<term>Ahas</term>
<term>Baseline</term>
<term>Blood pressure</term>
<term>Body weight</term>
<term>Cana</term>
<term>Chronic kidney disease</term>
<term>Core treatment period</term>
<term>Diabetes</term>
<term>Diabetes care</term>
<term>Diabetes mellitus</term>
<term>Diabetes obes metab</term>
<term>Discontinuation</term>
<term>Dos</term>
<term>Egfr</term>
<term>Endpoint</term>
<term>Fasting plasma glucose</term>
<term>Genital mycotic infections</term>
<term>Glucose</term>
<term>Glucose excretion</term>
<term>Glycaemic</term>
<term>Glycaemic control</term>
<term>Glycaemic rescue therapy</term>
<term>Glycemic control</term>
<term>Greater reductions</term>
<term>Gure</term>
<term>Hba1c</term>
<term>Hypoglycaemia</term>
<term>Hypoglycaemia episodes</term>
<term>Inhibitor</term>
<term>Insulin</term>
<term>Janssen research development</term>
<term>Last observation</term>
<term>Least squares</term>
<term>Lipoprotein cholesterol</term>
<term>Ltration rate</term>
<term>Median</term>
<term>Metabolism</term>
<term>Metabolism table</term>
<term>Metformin</term>
<term>Original article</term>
<term>Original article diabetes</term>
<term>Other reason</term>
<term>Percent change</term>
<term>Percent change difference</term>
<term>Percent changes</term>
<term>Placebo</term>
<term>Placebo group</term>
<term>Randomized</term>
<term>Randomized subjects</term>
<term>Renal</term>
<term>Renal disease</term>
<term>Renal function</term>
<term>Renal function parameters</term>
<term>Renal impairment</term>
<term>Renal threshold</term>
<term>Rescue therapy</term>
<term>Research support</term>
<term>Secondary endpoints</term>
<term>Sodium glucose</term>
<term>Standard deviation</term>
<term>Standard error</term>
<term>Statistical comparison</term>
<term>Study drug</term>
<term>Sulphonylurea</term>
<term>Sulphonylurea agent</term>
<term>T2dm</term>
<term>Time point</term>
<term>Transient changes</term>
<term>Treatment groups</term>
<term>Treatment period</term>
<term>Urine</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Adjustment period</term>
<term>Adverse event</term>
<term>Advisory panels</term>
<term>Ahas</term>
<term>Baseline</term>
<term>Blood pressure</term>
<term>Body weight</term>
<term>Cana</term>
<term>Chronic kidney disease</term>
<term>Core treatment period</term>
<term>Diabetes</term>
<term>Diabetes care</term>
<term>Diabetes mellitus</term>
<term>Diabetes obes metab</term>
<term>Discontinuation</term>
<term>Dos</term>
<term>Egfr</term>
<term>Endpoint</term>
<term>Fasting plasma glucose</term>
<term>Genital mycotic infections</term>
<term>Glucose</term>
<term>Glucose excretion</term>
<term>Glycaemic</term>
<term>Glycaemic control</term>
<term>Glycaemic rescue therapy</term>
<term>Glycemic control</term>
<term>Greater reductions</term>
<term>Gure</term>
<term>Hba1c</term>
<term>Hypoglycaemia</term>
<term>Hypoglycaemia episodes</term>
<term>Inhibitor</term>
<term>Insulin</term>
<term>Janssen research development</term>
<term>Last observation</term>
<term>Least squares</term>
<term>Lipoprotein cholesterol</term>
<term>Ltration rate</term>
<term>Median</term>
<term>Metabolism</term>
<term>Metabolism table</term>
<term>Metformin</term>
<term>Original article</term>
<term>Original article diabetes</term>
<term>Other reason</term>
<term>Percent change</term>
<term>Percent change difference</term>
<term>Percent changes</term>
<term>Placebo</term>
<term>Placebo group</term>
<term>Randomized</term>
<term>Randomized subjects</term>
<term>Renal</term>
<term>Renal disease</term>
<term>Renal function</term>
<term>Renal function parameters</term>
<term>Renal impairment</term>
<term>Renal threshold</term>
<term>Rescue therapy</term>
<term>Research support</term>
<term>Secondary endpoints</term>
<term>Sodium glucose</term>
<term>Standard deviation</term>
<term>Standard error</term>
<term>Statistical comparison</term>
<term>Study drug</term>
<term>Sulphonylurea</term>
<term>Sulphonylurea agent</term>
<term>T2dm</term>
<term>Time point</term>
<term>Transient changes</term>
<term>Treatment groups</term>
<term>Treatment period</term>
<term>Urine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Diabète</term>
<term>Glucose</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Canagliflozin is a sodium glucose co‐transporter 2 inhibitor in development for treatment of type 2 diabetes mellitus (T2DM). This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease [CKD; estimated glomerular filtration rate (eGFR) ≥30 and <50 ml/min/1.73 m2].</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Belgique</li>
<li>Brésil</li>
<li>Canada</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Illinois</li>
<li>Pays de la Loire</li>
<li>Québec</li>
<li>État de São Paulo</li>
</region>
<settlement><li>Chicago</li>
<li>Montréal</li>
<li>Nantes</li>
<li>São Paulo</li>
</settlement>
</list>
<tree><country name="Canada"><region name="Québec"><name sortKey="Yale, J" sort="Yale, J" uniqKey="Yale J" first="J." last="Yale">J. Yale</name>
</region>
<name sortKey="Yale, J" sort="Yale, J" uniqKey="Yale J" first="J." last="Yale">J. Yale</name>
</country>
<country name="États-Unis"><region name="Illinois"><name sortKey="Bakris, G" sort="Bakris, G" uniqKey="Bakris G" first="G." last="Bakris">G. Bakris</name>
</region>
<name sortKey="Figueroa, K" sort="Figueroa, K" uniqKey="Figueroa K" first="K." last="Figueroa">K. Figueroa</name>
<name sortKey="Meininger, G" sort="Meininger, G" uniqKey="Meininger G" first="G." last="Meininger">G. Meininger</name>
<name sortKey="Usiskin, K" sort="Usiskin, K" uniqKey="Usiskin K" first="K." last="Usiskin">K. Usiskin</name>
<name sortKey="Xi, L" sort="Xi, L" uniqKey="Xi L" first="L." last="Xi">L. Xi</name>
</country>
<country name="France"><region name="Pays de la Loire"><name sortKey="Cariou, B" sort="Cariou, B" uniqKey="Cariou B" first="B." last="Cariou">B. Cariou</name>
</region>
</country>
<country name="Australie"><noRegion><name sortKey="Yue, D" sort="Yue, D" uniqKey="Yue D" first="D." last="Yue">D. Yue</name>
</noRegion>
</country>
<country name="Brésil"><region name="État de São Paulo"><name sortKey="David Eto, E" sort="David Eto, E" uniqKey="David Eto E" first="E." last="David-Neto">E. David-Neto</name>
</region>
</country>
<country name="Belgique"><noRegion><name sortKey="Wajs, E" sort="Wajs, E" uniqKey="Wajs E" first="E." last="Wajs">E. Wajs</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Istex/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000386 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 000386 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Istex
   |étape=   Checkpoint
   |type=    RBID
   |clé=     ISTEX:3E46F81A4B18835C6DC50A5868041B88751EAA96
   |texte=   Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri